Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy
Elevated circulating levels of osteoprotegerin (OPG) are known to add to the prediction of cardiovascular mortality. Our objective was to clarify the long-term risk associated with serum OPG and the possible influence of diabetes and statins on OPG levels in patients with stable coronary artery disease (CAD).
Source: Atherosclerosis - Category: Cardiology Authors: Mette Bjerre, J ørgen Hilden, Per Winkel, Gorm Boje Jensen, Erik Kjøller, Ahmad Sajadieh, Jens Kastrup, Hans Jørn Kolmos, Anders Larsson, Johan Ärnlöv, Janus Christian Jakobsen, Christian Gluud Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Endocrinology | Heart | Statin Therapy